Loading…

Pivotal role of mitophagy in response of acute myelogenous leukemia to a ceramide-tamoxifen-containing drug regimen

Acute myelogenous leukemia (AML) is a hematological malignancy marked by the accumulation of large numbers of immature myeloblasts in bone marrow. The overall prognosis in AML is poor; hence, there is a pressing need to improve treatment. Although the sphingolipid (SL) ceramide demonstrates known ca...

Full description

Saved in:
Bibliographic Details
Published in:Experimental cell research 2019-08, Vol.381 (2), p.256-264
Main Authors: Morad, Samy A.F., MacDougall, Matthew R., Abdelmageed, Noha, Kao, Li-Pin, Feith, David J., Tan, Su-Fern, Kester, Mark, Loughran, Thomas P., Wang, Hong-Gang, Cabot, Myles C.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c525t-3f7dd2c00aeb84adb2fbfd24ecdd403e5ff278a87db262f1efd12e9855f3526f3
cites cdi_FETCH-LOGICAL-c525t-3f7dd2c00aeb84adb2fbfd24ecdd403e5ff278a87db262f1efd12e9855f3526f3
container_end_page 264
container_issue 2
container_start_page 256
container_title Experimental cell research
container_volume 381
creator Morad, Samy A.F.
MacDougall, Matthew R.
Abdelmageed, Noha
Kao, Li-Pin
Feith, David J.
Tan, Su-Fern
Kester, Mark
Loughran, Thomas P.
Wang, Hong-Gang
Cabot, Myles C.
description Acute myelogenous leukemia (AML) is a hematological malignancy marked by the accumulation of large numbers of immature myeloblasts in bone marrow. The overall prognosis in AML is poor; hence, there is a pressing need to improve treatment. Although the sphingolipid (SL) ceramide demonstrates known cancer suppressor properties, it’s mechanism of action is multifaceted. Our studies in leukemia and other cancers have demonstrated that when combined with the antiestrogen, tamoxifen, the apoptosis-inducting effect of ceramide is greatly enhanced. The goal of the present study was to establish whether a ceramide-tamoxifen regimen also affects autophagic-driven cellular responses in leukemia. Using the human AML cell line KG-1, we demonstrate that, unlike exposure to the single agents, combination C6-ceramide-tamoxifen upregulated LC3-II expression, inhibited the mTOR signaling pathway, and synergistically induced KG-1 cell death in an Atg5-dependent manner. In addition, colocalization of autophagosome and mitochondria, indicative of mitophagosome formation and mitophagy, was observed. Versatility of the drug regimen was confirmed by experiments in MV4-11 cells, a FLT3-ITD AML mutant. These results indicate that the C6-ceramide-tamoxifen regimen plays a pivotal role inducing autophagy in AML, and thus constitutes a novel therapeutic design. •Ceramide-tamoxifen regimen affects autophagic-driven responses in human AML cells.•Cell death with the regimen was Atg5-dependent and accompanied by mitophagy.•Inhibition of cell growth was associated with inhibition of mTOR signaling.
doi_str_mv 10.1016/j.yexcr.2019.05.021
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6909922</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014482719302629</els_id><sourcerecordid>2232100866</sourcerecordid><originalsourceid>FETCH-LOGICAL-c525t-3f7dd2c00aeb84adb2fbfd24ecdd403e5ff278a87db262f1efd12e9855f3526f3</originalsourceid><addsrcrecordid>eNp9kc1uFDEQhC0EIkvgCZCQj1xmsHv-DyChCEikSHCAs-W12xMvY3uxPavs2-NkQwQXTn2or6tbVYS85qzmjPfvdvURb1WsgfGpZl3NgD8hG84mVkEL8JRsGONt1Y4wnJEXKe0YY-PI--fkrOGcw9D0G5K-2UPIcqExLEiDoc7msL-R85FaTyOmffDpXpBqzUjdEZcwow9roguuP9FZSXOgkiqM0lmNVZYu3FqDvlLBZ2m99TPVcZ2L3Wwd-pfkmZFLwlcP85z8-Pzp-8Vldf31y9XFx-tKddDlqjGD1qAYk7gdW6m3YLZGQ4tK65Y12BkDwyjHoSg9GI5Gc8Bp7DrTdNCb5px8OPnu161DrdDnKBexj9bJeBRBWvGv4u2NmMNB9BObJoBi8PbBIIZfK6YsnE0Kl0V6LAGIggAvofZ9QZsTqmJIKaJ5PMOZuKtL7MR9XeKuLsE6UeoqW2_-_vBx508_BXh_ArDkdLAYRVIWvUJtI6osdLD_PfAby02sZg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2232100866</pqid></control><display><type>article</type><title>Pivotal role of mitophagy in response of acute myelogenous leukemia to a ceramide-tamoxifen-containing drug regimen</title><source>Elsevier</source><creator>Morad, Samy A.F. ; MacDougall, Matthew R. ; Abdelmageed, Noha ; Kao, Li-Pin ; Feith, David J. ; Tan, Su-Fern ; Kester, Mark ; Loughran, Thomas P. ; Wang, Hong-Gang ; Cabot, Myles C.</creator><creatorcontrib>Morad, Samy A.F. ; MacDougall, Matthew R. ; Abdelmageed, Noha ; Kao, Li-Pin ; Feith, David J. ; Tan, Su-Fern ; Kester, Mark ; Loughran, Thomas P. ; Wang, Hong-Gang ; Cabot, Myles C.</creatorcontrib><description>Acute myelogenous leukemia (AML) is a hematological malignancy marked by the accumulation of large numbers of immature myeloblasts in bone marrow. The overall prognosis in AML is poor; hence, there is a pressing need to improve treatment. Although the sphingolipid (SL) ceramide demonstrates known cancer suppressor properties, it’s mechanism of action is multifaceted. Our studies in leukemia and other cancers have demonstrated that when combined with the antiestrogen, tamoxifen, the apoptosis-inducting effect of ceramide is greatly enhanced. The goal of the present study was to establish whether a ceramide-tamoxifen regimen also affects autophagic-driven cellular responses in leukemia. Using the human AML cell line KG-1, we demonstrate that, unlike exposure to the single agents, combination C6-ceramide-tamoxifen upregulated LC3-II expression, inhibited the mTOR signaling pathway, and synergistically induced KG-1 cell death in an Atg5-dependent manner. In addition, colocalization of autophagosome and mitochondria, indicative of mitophagosome formation and mitophagy, was observed. Versatility of the drug regimen was confirmed by experiments in MV4-11 cells, a FLT3-ITD AML mutant. These results indicate that the C6-ceramide-tamoxifen regimen plays a pivotal role inducing autophagy in AML, and thus constitutes a novel therapeutic design. •Ceramide-tamoxifen regimen affects autophagic-driven responses in human AML cells.•Cell death with the regimen was Atg5-dependent and accompanied by mitophagy.•Inhibition of cell growth was associated with inhibition of mTOR signaling.</description><identifier>ISSN: 0014-4827</identifier><identifier>EISSN: 1090-2422</identifier><identifier>DOI: 10.1016/j.yexcr.2019.05.021</identifier><identifier>PMID: 31112736</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Autophagy ; Ceramide ; Leukemia ; Mitophagy ; Sphingolipids ; Tamoxifen</subject><ispartof>Experimental cell research, 2019-08, Vol.381 (2), p.256-264</ispartof><rights>2019 Elsevier Inc.</rights><rights>Copyright © 2019 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c525t-3f7dd2c00aeb84adb2fbfd24ecdd403e5ff278a87db262f1efd12e9855f3526f3</citedby><cites>FETCH-LOGICAL-c525t-3f7dd2c00aeb84adb2fbfd24ecdd403e5ff278a87db262f1efd12e9855f3526f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31112736$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Morad, Samy A.F.</creatorcontrib><creatorcontrib>MacDougall, Matthew R.</creatorcontrib><creatorcontrib>Abdelmageed, Noha</creatorcontrib><creatorcontrib>Kao, Li-Pin</creatorcontrib><creatorcontrib>Feith, David J.</creatorcontrib><creatorcontrib>Tan, Su-Fern</creatorcontrib><creatorcontrib>Kester, Mark</creatorcontrib><creatorcontrib>Loughran, Thomas P.</creatorcontrib><creatorcontrib>Wang, Hong-Gang</creatorcontrib><creatorcontrib>Cabot, Myles C.</creatorcontrib><title>Pivotal role of mitophagy in response of acute myelogenous leukemia to a ceramide-tamoxifen-containing drug regimen</title><title>Experimental cell research</title><addtitle>Exp Cell Res</addtitle><description>Acute myelogenous leukemia (AML) is a hematological malignancy marked by the accumulation of large numbers of immature myeloblasts in bone marrow. The overall prognosis in AML is poor; hence, there is a pressing need to improve treatment. Although the sphingolipid (SL) ceramide demonstrates known cancer suppressor properties, it’s mechanism of action is multifaceted. Our studies in leukemia and other cancers have demonstrated that when combined with the antiestrogen, tamoxifen, the apoptosis-inducting effect of ceramide is greatly enhanced. The goal of the present study was to establish whether a ceramide-tamoxifen regimen also affects autophagic-driven cellular responses in leukemia. Using the human AML cell line KG-1, we demonstrate that, unlike exposure to the single agents, combination C6-ceramide-tamoxifen upregulated LC3-II expression, inhibited the mTOR signaling pathway, and synergistically induced KG-1 cell death in an Atg5-dependent manner. In addition, colocalization of autophagosome and mitochondria, indicative of mitophagosome formation and mitophagy, was observed. Versatility of the drug regimen was confirmed by experiments in MV4-11 cells, a FLT3-ITD AML mutant. These results indicate that the C6-ceramide-tamoxifen regimen plays a pivotal role inducing autophagy in AML, and thus constitutes a novel therapeutic design. •Ceramide-tamoxifen regimen affects autophagic-driven responses in human AML cells.•Cell death with the regimen was Atg5-dependent and accompanied by mitophagy.•Inhibition of cell growth was associated with inhibition of mTOR signaling.</description><subject>Autophagy</subject><subject>Ceramide</subject><subject>Leukemia</subject><subject>Mitophagy</subject><subject>Sphingolipids</subject><subject>Tamoxifen</subject><issn>0014-4827</issn><issn>1090-2422</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kc1uFDEQhC0EIkvgCZCQj1xmsHv-DyChCEikSHCAs-W12xMvY3uxPavs2-NkQwQXTn2or6tbVYS85qzmjPfvdvURb1WsgfGpZl3NgD8hG84mVkEL8JRsGONt1Y4wnJEXKe0YY-PI--fkrOGcw9D0G5K-2UPIcqExLEiDoc7msL-R85FaTyOmffDpXpBqzUjdEZcwow9roguuP9FZSXOgkiqM0lmNVZYu3FqDvlLBZ2m99TPVcZ2L3Wwd-pfkmZFLwlcP85z8-Pzp-8Vldf31y9XFx-tKddDlqjGD1qAYk7gdW6m3YLZGQ4tK65Y12BkDwyjHoSg9GI5Gc8Bp7DrTdNCb5px8OPnu161DrdDnKBexj9bJeBRBWvGv4u2NmMNB9BObJoBi8PbBIIZfK6YsnE0Kl0V6LAGIggAvofZ9QZsTqmJIKaJ5PMOZuKtL7MR9XeKuLsE6UeoqW2_-_vBx508_BXh_ArDkdLAYRVIWvUJtI6osdLD_PfAby02sZg</recordid><startdate>20190815</startdate><enddate>20190815</enddate><creator>Morad, Samy A.F.</creator><creator>MacDougall, Matthew R.</creator><creator>Abdelmageed, Noha</creator><creator>Kao, Li-Pin</creator><creator>Feith, David J.</creator><creator>Tan, Su-Fern</creator><creator>Kester, Mark</creator><creator>Loughran, Thomas P.</creator><creator>Wang, Hong-Gang</creator><creator>Cabot, Myles C.</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20190815</creationdate><title>Pivotal role of mitophagy in response of acute myelogenous leukemia to a ceramide-tamoxifen-containing drug regimen</title><author>Morad, Samy A.F. ; MacDougall, Matthew R. ; Abdelmageed, Noha ; Kao, Li-Pin ; Feith, David J. ; Tan, Su-Fern ; Kester, Mark ; Loughran, Thomas P. ; Wang, Hong-Gang ; Cabot, Myles C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c525t-3f7dd2c00aeb84adb2fbfd24ecdd403e5ff278a87db262f1efd12e9855f3526f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Autophagy</topic><topic>Ceramide</topic><topic>Leukemia</topic><topic>Mitophagy</topic><topic>Sphingolipids</topic><topic>Tamoxifen</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Morad, Samy A.F.</creatorcontrib><creatorcontrib>MacDougall, Matthew R.</creatorcontrib><creatorcontrib>Abdelmageed, Noha</creatorcontrib><creatorcontrib>Kao, Li-Pin</creatorcontrib><creatorcontrib>Feith, David J.</creatorcontrib><creatorcontrib>Tan, Su-Fern</creatorcontrib><creatorcontrib>Kester, Mark</creatorcontrib><creatorcontrib>Loughran, Thomas P.</creatorcontrib><creatorcontrib>Wang, Hong-Gang</creatorcontrib><creatorcontrib>Cabot, Myles C.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Experimental cell research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Morad, Samy A.F.</au><au>MacDougall, Matthew R.</au><au>Abdelmageed, Noha</au><au>Kao, Li-Pin</au><au>Feith, David J.</au><au>Tan, Su-Fern</au><au>Kester, Mark</au><au>Loughran, Thomas P.</au><au>Wang, Hong-Gang</au><au>Cabot, Myles C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pivotal role of mitophagy in response of acute myelogenous leukemia to a ceramide-tamoxifen-containing drug regimen</atitle><jtitle>Experimental cell research</jtitle><addtitle>Exp Cell Res</addtitle><date>2019-08-15</date><risdate>2019</risdate><volume>381</volume><issue>2</issue><spage>256</spage><epage>264</epage><pages>256-264</pages><issn>0014-4827</issn><eissn>1090-2422</eissn><abstract>Acute myelogenous leukemia (AML) is a hematological malignancy marked by the accumulation of large numbers of immature myeloblasts in bone marrow. The overall prognosis in AML is poor; hence, there is a pressing need to improve treatment. Although the sphingolipid (SL) ceramide demonstrates known cancer suppressor properties, it’s mechanism of action is multifaceted. Our studies in leukemia and other cancers have demonstrated that when combined with the antiestrogen, tamoxifen, the apoptosis-inducting effect of ceramide is greatly enhanced. The goal of the present study was to establish whether a ceramide-tamoxifen regimen also affects autophagic-driven cellular responses in leukemia. Using the human AML cell line KG-1, we demonstrate that, unlike exposure to the single agents, combination C6-ceramide-tamoxifen upregulated LC3-II expression, inhibited the mTOR signaling pathway, and synergistically induced KG-1 cell death in an Atg5-dependent manner. In addition, colocalization of autophagosome and mitochondria, indicative of mitophagosome formation and mitophagy, was observed. Versatility of the drug regimen was confirmed by experiments in MV4-11 cells, a FLT3-ITD AML mutant. These results indicate that the C6-ceramide-tamoxifen regimen plays a pivotal role inducing autophagy in AML, and thus constitutes a novel therapeutic design. •Ceramide-tamoxifen regimen affects autophagic-driven responses in human AML cells.•Cell death with the regimen was Atg5-dependent and accompanied by mitophagy.•Inhibition of cell growth was associated with inhibition of mTOR signaling.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>31112736</pmid><doi>10.1016/j.yexcr.2019.05.021</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0014-4827
ispartof Experimental cell research, 2019-08, Vol.381 (2), p.256-264
issn 0014-4827
1090-2422
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6909922
source Elsevier
subjects Autophagy
Ceramide
Leukemia
Mitophagy
Sphingolipids
Tamoxifen
title Pivotal role of mitophagy in response of acute myelogenous leukemia to a ceramide-tamoxifen-containing drug regimen
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T23%3A56%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pivotal%20role%20of%20mitophagy%20in%20response%20of%20acute%20myelogenous%20leukemia%20to%20a%20ceramide-tamoxifen-containing%20drug%20regimen&rft.jtitle=Experimental%20cell%20research&rft.au=Morad,%20Samy%20A.F.&rft.date=2019-08-15&rft.volume=381&rft.issue=2&rft.spage=256&rft.epage=264&rft.pages=256-264&rft.issn=0014-4827&rft.eissn=1090-2422&rft_id=info:doi/10.1016/j.yexcr.2019.05.021&rft_dat=%3Cproquest_pubme%3E2232100866%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c525t-3f7dd2c00aeb84adb2fbfd24ecdd403e5ff278a87db262f1efd12e9855f3526f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2232100866&rft_id=info:pmid/31112736&rfr_iscdi=true